Reuters logo
5 months ago
BRIEF-Medtronic says data from surtavi trial showed co's self-expanding TAVR platform met primary endpoint at 2 years
March 17, 2017 / 1:28 PM / 5 months ago

BRIEF-Medtronic says data from surtavi trial showed co's self-expanding TAVR platform met primary endpoint at 2 years

March 17 (Reuters) - Medtronic Plc

* Landmark surtavi clinical trial shows transcatheter aortic valve replacement (tavr) with the self-expanding platform performs as well as surgery in intermediate risk severe aortic stenosis patients

* Medtronic plc- data from surtavi trial showed co's self-expanding tavr platform met primary endpoint at 2 years

* Medtronic plc - results of surtavi trial have been submitted to fda to support an intermediate risk label expansion Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below